18 May 2013
Keywords: dor, biopharma, starts, orbec, npap, asean, region
Article | 01 September 2008
DOR BioPharma, a late-stage, US biopharmaceutical company developing products to treat the life-threatening side effects of cancer therapies
and serious ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 September 2008
17 May 2013
© 2013 thepharmaletter.com